Showing results (211-220 of 296) with videos related to

Sort By:
Pageof 30
Open Forum Infectious Diseases|May 30, 2019
Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and CanadaDavid R McGivern, Hsing-Hua S Lin, Junyao Wang, et al.
Hepatology (Baltimore, Md.)|September 26, 2002
Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirinMichael W Fried, Joy Peter, Keith Hoots, et al.
Hepatology (Baltimore, Md.)|January 29, 2008
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis BMichael W Fried, Teerha Piratvisuth, George K K Lau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020
Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United StatesMichael W Fried, Julie M Crawford, Andrea R Mospan, et al.
Hepatology (Baltimore, Md.)|September 1, 1992
A pilot study of ribavirin therapy for chronic hepatitis CA M Di Bisceglie, M Shindo, T L Fong, et al.
Epidemiology (Cambridge, Mass.)|January 31, 2023
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial EmulationAlexander Breskin, Catherine Wiener, Adaora A Adimora, et al.
Hepatology Communications|June 19, 2026
Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratificationPhilip N Newsome, Claudio Sartini, Heather L Morris, et al.
Chemmedchem|March 31, 2007
From dioxin to drug lead--the development of 2,3,7,8-tetrachlorophenothiazineKristian W Fried, Christopher M Schneider, Karl-Werner Schramm, et al.
Journal of Hepatology|September 10, 2002
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee, E Jenny Heathcote, K Rajender Reddy, et al.
The American Journal of Gastroenterology|July 6, 2004
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trialPaul J Pockros, Robert Carithers, Paul Desmond, et al.
Pageof 30